Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB8J2U
|
|||
| Drug Name |
KPG-818
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 1 | [1] | |
| Company |
Kangpu Biopharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04643067) A Study to Assess the Safety and Tolerability, PK and Efficacy of KPG-818 in Mild to Moderate SLE Patients (Lupus). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Kangpu Biopharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.